Form 4: Sangamo Therapeutics Executive Reports Stock Transactions

Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, reports stock transactions including vesting of restricted stock units and associated tax withholding.

Summary

• Scott B. Willoughby, a senior executive at Sangamo Therapeutics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On February 24, 2025, 1,434 shares were disposed of to cover tax obligations related to vesting RSUs at a price of $1.00 per share.
• On February 25, 2025, 1,375 shares were disposed of to cover tax obligations related to vesting RSUs at a price of $0.9561 per share.
• Also on February 25, 2025, 120,000 shares were acquired through the vesting of a RSU grant.
• Additionally, on February 25, 2025, Willoughby was granted an option to purchase 560,000 shares of common stock at an exercise price of $0.9561.
• Following these transactions, Willoughby beneficially owns 814,842 shares of Sangamo Therapeutics stock and options to purchase 560,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. There are no indications of unusual activity or concerns.

Positives

• The granting of stock options and RSUs to executives aligns their interests with those of shareholders.
• The vesting of RSUs indicates continued service and commitment by the executive.

Future Outlook

The reported RSU grants will continue to vest in quarterly installments through February 24, 2026, and January 22, 2026, subject to continuous service.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain talent.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize equity-based compensation.
• The vesting schedules and terms are generally consistent with industry norms.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they relate to executive compensation and do not indicate a change in the company's fundamentals.
• Employees who are also shareholders may be interested in the stock price and vesting schedules.

Key Dates